Latvja - Latvjan - Zāļu valsts aģentūra

astellas pharma d.o.o., slovenia - solifenacini succinas, tamsulosini hydrochloridum - modificētās darbības tablete - 6 mg/0,4 mg

Latvja - Latvjan - Zāļu valsts aģentūra

astellas pharma d.o.o., slovenia - solifencīna sukcināts - suspensija iekšķīgai lietošanai - 1 mg/ml

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

leo pharma a/s - tacrolimus - dermatīts, atopisks - citi dermatoloģiski preparāti - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. sastopamas četras vai vairāk reizes gadā), kas ir bijusi pirmā atbilde, lai maksimāli sešas nedēļas ārstēšanai divreiz dienā takrolīma ziede (bojājumi noskaidroti, gandrīz noskaidroti vai daļēji ietekmē).

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastiski līdzekļi - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - prostatas audzēji - endokrīnā terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

astellas pharma europe b.v. - gilteritinib fumarate - leikēmija, mieloīds, akūts - antineoplastiski līdzekļi - xospata ir norādīts kā monotherapy ārstēšanai pieaugušiem pacientiem, kuriem ir relapsed vai ugunsizturīgs akūtu mieloīdu leikozi (aml) ar flt3 mutācijas.

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianēmiski līdzekļi - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - dalbavancin hydrochloride - soft tissue infections; skin diseases, bacterial - antibakteriālas līdzekļi sistēmiskai lietošanai, - acu bakteriālas ādas un ādas struktūras infekcijas (absssi) ārstēšana pieaugušajiem.

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - oritavancin (diphosphate) - soft tissue infections; skin diseases, bacterial - antibakteriālas līdzekļi sistēmiskai lietošanai, - tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and paediatric patients aged 3 months and older (see sections 4. 2, 4. 4 un 5. jāņem vērā oficiālās vadlīnijas par piemērotu izmantot antibakteriālas vielas.

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

janssen-cilag international nv - simeprevir - c hepatīts, hronisks - pretvīrusu līdzekļi sistēmiskai lietošanai - olysio ir indicēts kombinācijā ar citām zālēm pieaugušiem pacientiem hroniska c hepatīta (chc) ārstēšanai. hepatīta c vīrusa (hcv) genotipa specifiska aktivitāte.